MX349169B - Ophthalmic pharmaceutical compositions and methods of making and using same. - Google Patents

Ophthalmic pharmaceutical compositions and methods of making and using same.

Info

Publication number
MX349169B
MX349169B MX2014009620A MX2014009620A MX349169B MX 349169 B MX349169 B MX 349169B MX 2014009620 A MX2014009620 A MX 2014009620A MX 2014009620 A MX2014009620 A MX 2014009620A MX 349169 B MX349169 B MX 349169B
Authority
MX
Mexico
Prior art keywords
polymer
oil
emulsion
making
methods
Prior art date
Application number
MX2014009620A
Other languages
Spanish (es)
Other versions
MX2014009620A (en
Inventor
R Davio Stephen
Sarkar Paramita
T Marlowe Zora
J Glass Brian
J Kleiber Tammy
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of MX2014009620A publication Critical patent/MX2014009620A/en
Publication of MX349169B publication Critical patent/MX349169B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A stable ophthalmic pharmaceutical composition for relief, treatment, control, alleviation, or prevention of a pathological ocular condition of the eye comprises: (a) a first polymer, a viscosity of which changes with a change in a concentration of an electrolyte, such as a salt, when added to said first polymer; (b) a second polymer that is different from the first polymer and can modify the viscosity of the first polymer; and (c) an oil. In some embodiments, the composition further comprises a non-ionic surfactant. The composition can form a stable oil-in-water emulsion on storage, but separate into an oil phase and a water phase when applied in the eye. The emulsion can comprises an ophthalmic active pharmaceutical ingredient dissolved in the oil or water phase. The emulsion can provide enhanced stability to said active pharmaceutical ingredient.
MX2014009620A 2012-02-13 2013-02-07 Ophthalmic pharmaceutical compositions and methods of making and using same. MX349169B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261597879P 2012-02-13 2012-02-13
US13/739,018 US9278132B2 (en) 2012-02-13 2013-01-11 Ophthalmic pharmaceutical compositions and methods of making and using same
PCT/US2013/025013 WO2013122801A1 (en) 2012-02-13 2013-02-07 Ophthalmic pharmaceutical compositions and methods of making and using same

Publications (2)

Publication Number Publication Date
MX2014009620A MX2014009620A (en) 2014-11-10
MX349169B true MX349169B (en) 2017-07-17

Family

ID=48946121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009620A MX349169B (en) 2012-02-13 2013-02-07 Ophthalmic pharmaceutical compositions and methods of making and using same.

Country Status (14)

Country Link
US (1) US9278132B2 (en)
EP (1) EP2814463B1 (en)
JP (1) JP5898789B2 (en)
KR (1) KR101760990B1 (en)
CN (1) CN104203215B (en)
AR (1) AR089962A1 (en)
AU (1) AU2013219822B2 (en)
CA (1) CA2864417C (en)
ES (1) ES2576113T3 (en)
HU (1) HUE029276T2 (en)
MX (1) MX349169B (en)
PL (1) PL2814463T3 (en)
TW (1) TWI535462B (en)
WO (1) WO2013122801A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
JP6537775B2 (en) * 2014-03-10 2019-07-03 小林製薬株式会社 Emulsified composition
US10245324B2 (en) 2014-10-31 2019-04-02 Johnson & Johnson Consumer Inc. Ophthalmic composition
US20190231885A1 (en) 2015-11-10 2019-08-01 Sun Pharma Global Fze Topical formulations and uses thereof
CN109843316A (en) 2016-02-29 2019-06-04 太阳制药全球公司 Topical formulations and application thereof containing cyclosporin
EP3231417B1 (en) * 2016-04-15 2018-12-05 Dr. Gerhard Mann Chem.-Pharm. Fabrik GmbH Storage stable, ophthalmic compound
IL269133B2 (en) 2017-03-05 2024-09-01 Resdevco Res And Development Co Ltd Eye Drops for Treatment of Sj?gren's Syndrom
US10933111B2 (en) * 2019-01-08 2021-03-02 Boston Biotechnology US CORP Treating dry eye disorders
DE102021212692A1 (en) 2021-11-11 2023-05-11 Ursapharm Arzneimittel Gmbh SELF-EMULSIFYING OIL-IN-WATER MICRO- OR NANO-EMULSION AND EMULSIFYING COMPOSITION

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US5209927A (en) 1985-01-23 1993-05-11 Alcon Laboratories, Inc. Ophthalmic solution
DE69115990T2 (en) 1990-05-29 1996-05-30 Ocular Res Of Bonton Inc Composition for the treatment of dry eye diseases
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
ES2094688B1 (en) * 1994-08-08 1997-08-01 Cusi Lab MANOEMULSION OF THE TYPE OF OIL IN WATER, USEFUL AS AN OPHTHALMIC VEHICLE AND PROCEDURE FOR ITS PREPARATION.
EP0878197B1 (en) * 1997-05-14 2002-08-21 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
CN1456157A (en) 2002-05-10 2003-11-19 刘继东 Ophthalmic gel of L-ofloxacin
CN1180776C (en) 2002-12-02 2004-12-22 刘继东 Ofloxacin eye ointment
ES2331313T3 (en) * 2003-11-07 2009-12-29 Senju Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING PROSTAGLANDIN.
US9161905B2 (en) * 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
NO2437762T3 (en) 2009-06-05 2018-01-06
FR2962044B1 (en) * 2010-04-21 2013-02-22 Horus Pharma LACRYMIMETIC EMULSION
FR2961694B1 (en) 2010-06-29 2013-01-25 Thea Lab POLYMERIC DELIVERY SYSTEM FOR NON-VISCOUS SOLUTION BASED ON PROSTAGLANDIN WITHOUT PRESERVATIVE
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
KR101760990B1 (en) 2017-07-24
MX2014009620A (en) 2014-11-10
EP2814463B1 (en) 2016-05-18
PL2814463T3 (en) 2016-11-30
US20130210912A1 (en) 2013-08-15
ES2576113T3 (en) 2016-07-05
CN104203215A (en) 2014-12-10
AU2013219822A1 (en) 2014-08-28
CA2864417C (en) 2018-10-16
CA2864417A1 (en) 2013-08-22
TW201345564A (en) 2013-11-16
JP5898789B2 (en) 2016-04-06
AR089962A1 (en) 2014-10-01
JP2015507010A (en) 2015-03-05
KR20140121479A (en) 2014-10-15
US9278132B2 (en) 2016-03-08
CN104203215B (en) 2017-04-12
HUE029276T2 (en) 2017-02-28
AU2013219822B2 (en) 2016-01-14
WO2013122801A1 (en) 2013-08-22
TWI535462B (en) 2016-06-01
EP2814463A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
MX349169B (en) Ophthalmic pharmaceutical compositions and methods of making and using same.
WO2016172712A3 (en) Ophthalmic composition
MX2018006919A (en) Inverse emulsion compositions.
TW201613588A (en) Ophthalmic composition
WO2015094415A3 (en) Glycerin-in-oil emulsion
PH12016502205A1 (en) Biphasic cosmetic
MX2013002932A (en) Liquid agricultural formulations of improved stability.
EP4302734A3 (en) Ocular delivery systems and methods
MX370903B (en) Stable percarboxylic acid compositions and uses thereof.
FI2887923T3 (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2010111267A3 (en) Personal-care composition comprising a cationic active
MX2023003124A (en) Ophthalmic pharmaceutical compositions and uses relating thereto.
WO2013130948A3 (en) Sunscreen composition comprising uv composite
CL2013002134A1 (en) Topical administration ophthalmic pharmaceutical composition comprising an androgen; and method to treat an eye condition resulting from an androgen deficiency.
RU2014115278A (en) COSMETIC EMULSION TYPE "OIL IN WATER"
NZ603345A (en) Stabilized ophthalmic galactomannan formulations
MX2018006918A (en) Liquid polymer compositions.
BR112018011157A2 (en) agrochemical composition of aqueous suspension.
MY196111A (en) Suspension Compositions of Cyclosporin a for Subconjunctival and Periocular Injection
EA201201239A1 (en) A composition comprising as active ingredients L-CARNITINE IN COMBINATION WITH hydroxykynurenine-O-BETA-DL-glucoside FOR PREVENTING AND / OR TREATING PATHOLOGIES eyes caused by ultraviolet radiation
WO2014097258A3 (en) Aqueous cosmetic composition comprising alkylcellulose
EA201690532A1 (en) NO CONSERVATIVE OPHTHALMOLOGIC PHARMACEUTICAL COMPOSITION
EA201291335A1 (en) PHARMACEUTICAL COMPOSITIONS FOR LOCAL APPLICATION
IN2014MN00929A (en)
JP2015504860A5 (en)

Legal Events

Date Code Title Description
FG Grant or registration